Related references
Note: Only part of the references are listed.Bi38-3 is a novel CD38/CD3 bispecific T-cell engager with low toxicity for the treatment of multiple myeloma
Maxime Fayon et al.
HAEMATOLOGICA (2021)
Cancer Statistics, 2021
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2021)
Cevostamab Monotherapy Continues to Show Clinically Meaningful Activity and Manageable Safety in Patients with Heavily Pre-Treated Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results from an Ongoing Phase I Study
Suzanne Trudel et al.
BLOOD (2021)
Early, Deep, and Durable Responses, and Low Rates of Cytokine Release Syndrome with REGN5458, a BCMAxCD3 Bispecific Monoclonal Antibody, in a Phase 1/2 First-in-Human Study in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)
Jeffrey A. Zonder et al.
BLOOD (2021)
A Phase 1 First-in-Human Study of Tnb-383B, a BCMA x CD3 Bispecific T-Cell Redirecting Antibody, in Patients with Relapsed/Refractory Multiple Myeloma
Shaji Kumar et al.
BLOOD (2021)
Updated Phase 1 Results from MonumenTAL-1: First-in-Human Study of Talquetamab, a G Protein-Coupled Receptor Family C Group 5 Member D x CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma
Amrita Y. Krishnan et al.
BLOOD (2021)
How I Manage: Pathophysiology and Management of Toxicity of Chimeric Antigen Receptor T-Cell Therapies
Patrick M. Reagan et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Nanoparticle T-cell engagers as a modular platform for cancer immunotherapy
Kinan Alhallak et al.
LEUKEMIA (2021)
Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma
Nikhil C. Munshi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
The Immune Microenvironment in Multiple Myeloma: Friend or Foe?
Raquel Lopes et al.
CANCERS (2021)
A BCMAxCD3 bispecific T cell-engaging antibody demonstrates robust antitumor efficacy similar to that of anti-BCMA CAR T cells
David J. DiLillo et al.
BLOOD ADVANCES (2021)
ISB 1342: A first-in-class CD38 T cell engager for the treatment of relapsed refractory multiple myeloma.
Marie-Agnes Doucey et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Updated phase 1 results of teclistamab, a B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in relapsed/refractory multiple myeloma (MM).
Amrita Y. Krishnan et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Teclistamab, a B-cell maturation antigenxCD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study
Saad Z. Usmani et al.
LANCET (2021)
Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial
Philippe Moreau et al.
LANCET (2021)
Ciltacabtagene autoleucel, a B-cell maturation antigendirected chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study
Jesus G. Berdeja et al.
LANCET (2021)
Updated Results from MajesTEC-1: Phase 1/2 Study of Teclistamab, a B-Cell Maturation Antigen x CD3 Bispecific Antibody, in Relapsed/Refractory Multiple Myeloma
Philippe Moreau et al.
BLOOD (2021)
Elranatamab (PF-06863135), a B-Cell Maturation Antigen (BCMA) Targeted CD3-Engaging Bispecific Molecule, for Patients with Relapsed or Refractory Multiple Myeloma: Results from Magnetismm-1
Michael Sebag et al.
BLOOD (2021)
T Cell Transcriptional Profiling and Immunophenotyping Uncover LAG3 as a Potential Significant Target of Immune Modulation in Multiple Myeloma
Fabienne Lucas et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2020)
Anti-B-Cell Maturation Antigen BiTE Molecule AMG 420 Induces Responses in Multiple Myeloma
Max S. Topp et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study
Sagar Lonial et al.
LANCET ONCOLOGY (2020)
B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches
Nina Shah et al.
LEUKEMIA (2020)
Challenges for Immunotherapy in Multiple Myeloma: Bone Marrow Microenvironment-Mediated Immune Suppression and Immune Resistance
Lisa C. Holthof et al.
CANCERS (2020)
AMG 701 induces cytotoxicity of multiple myeloma cells and depletes plasma cells in cynomolgus monkeys
Rebecca L. Goldstein et al.
BLOOD ADVANCES (2020)
Teclistamab is an active T cell-redirecting bispecific antibody against B-cell maturation antigen for multiple myeloma
Kodandaram Pillarisetti et al.
BLOOD ADVANCES (2020)
Preclinical pharmacology and safety of RO7297089, a novel anti-BCMA/CD16a bispecific antibody for the treatment of multiple myeloma
Satoko Kakiuchi-Kiyota et al.
CANCER RESEARCH (2020)
A Phase 1 First in Human (FIH) Study of AMG 701, an Anti-B-Cell Maturation Antigen (BCMA) Half-Life Extended (HLE) BiTE® (bispecific T-cell engager) Molecule, in Relapsed/Refractory (RR) Multiple Myeloma (MM)
Simon J. Harrison et al.
BLOOD (2020)
REGN5458, a BCMA x CD3 Bispecific Monoclonal Antibody, Induces Deep and Durable Responses in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)
Deepu Madduri et al.
BLOOD (2020)
Targeting Multiple Myeloma with AMG 424, a Novel Anti-CD38/CD3 Bispecific T-cell-recruiting Antibody Optimized for Cytotoxicity and Cytokine Release
Christina L. Zuch de Zafra et al.
CLINICAL CANCER RESEARCH (2019)
GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells
Eric L. Smith et al.
SCIENCE TRANSLATIONAL MEDICINE (2019)
Phase I trial of isatuximab monotherapy in the treatment of refractory multiple myeloma
Thomas Martin et al.
BLOOD CANCER JOURNAL (2019)
PD-L1, LAG3, and HLA-DR are increasingly expressed during smoldering myeloma progression
Alberto Mussetti et al.
ANNALS OF HEMATOLOGY (2019)
A review of bispecific antibodies and antibody constructs in oncology and clinical challenges
Frans V. Suurs et al.
PHARMACOLOGY & THERAPEUTICS (2019)
Managing the toxicities of CAR T-cell therapy
Sattva S. Neelapu
HEMATOLOGICAL ONCOLOGY (2019)
Anti-GPRC5D/CD3 Bispecific T-Cell-Redirecting Antibody for the Treatment of Multiple Myeloma
Tatsushi Kodama et al.
MOLECULAR CANCER THERAPEUTICS (2019)
Oral Selinexor-Dexamethasone for Triple-Class Refractory Multiple Myeloma
Ajai Chari et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
TNB383B.0001: A Multicenter, Phase 1, Open-Label, Dose-Escalation Andexpansion Study of TNB-383B, a Bispecific Antibodytargeting BCMA in Subjects with Relapsed or Refractorymultiple Myeloma
Ben Buelow et al.
BLOOD (2019)
ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells
Daniel W. Lee et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2019)
First Clinical Study of the B-Cell Maturation Antigen (BCMA) 2+1 T Cell Engager (TCE) CC-93269 in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Interim Results of a Phase 1 Multicenter Trial
Luciano J. Costa et al.
BLOOD (2019)
A robust heterodimeric Fc platform engineered for efficient development of bispecific antibodies of multiple formats
Gregory L. Moore et al.
METHODS (2019)
Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study
Michel Attal et al.
LANCET (2019)
Multispecific Antibody Development Platform Based on Human Heavy Chain Antibodies
Starlynn C. Clarke et al.
FRONTIERS IN IMMUNOLOGY (2019)
Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma
M. -V. Mateos et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Sequence-Based Discovery Demonstrates That Fixed Light Chain Human Transgenic Rats Produce a Diverse Repertoire of Antigen-Specific Antibodies
Katherine E. Harris et al.
FRONTIERS IN IMMUNOLOGY (2018)
Phase 3 Randomized Study of Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Ineligible for Transplant (MAIA)
Thierry Facon et al.
BLOOD (2018)
AFM26 is a novel, highly potent BCMA/CD16A-directed bispecific antibody for high affinity NK-cell engagement in multiple myeloma.
Thorsten Gantke et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Membrane-Proximal Epitope Facilitates Efficient T Cell Synapse Formation by Anti-FcRH5/CD3 and Is a Requirement for Myeloma Cell Killing
Ji Li et al.
CANCER CELL (2017)
Target Expression, Generation, Preclinical Activity, and Pharmacokinetics of the BCMA-T Cell Bispecific Antibody EM801 for Multiple Myeloma Treatment
Anja Seckinger et al.
CANCER CELL (2017)
Dissecting the multiple myeloma-bone microenvironment reveals new therapeutic opportunities
G. Shay et al.
JOURNAL OF MOLECULAR MEDICINE-JMM (2016)
Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial
Sagar Lonial et al.
LANCET (2016)
Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma
M. A. Dimopoulos et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma
Antonio Palumbo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Multiple myeloma epidemiology and survival: A unique malignancy
Dickran Kazandjian
SEMINARS IN ONCOLOGY (2016)
Immunotherapy based on bispecific T-cell engager with hIgG1 Fc sequence as a new therapeutic strategy in multiple myeloma
Jianxuan Zou et al.
CANCER SCIENCE (2015)
γ-secretase directly sheds the survival receptor BCMA from plasma cells
Sarah A. Laurent et al.
NATURE COMMUNICATIONS (2015)
Tumor cells in multiple myeloma patients inhibit myeloma-reactive T cells through carcinoembryonic antigen-related cell adhesion molecule-6
Mathias Witzens-Harig et al.
BLOOD (2013)
B-cell Maturation Antigen Is a Promising Target for Adoptive T-cell Therapy of Multiple Myeloma
Robert O. Carpenter et al.
CLINICAL CANCER RESEARCH (2013)
Serum B-cell maturation antigen is elevated in multiple myeloma and correlates with disease status and survival
Eric Sanchez et al.
BRITISH JOURNAL OF HAEMATOLOGY (2012)
Overexpression of G protein-coupled receptor 5D in the bone marrow is associated with poor prognosis in patients with multiple myeloma
Johanna Atamaniuk et al.
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION (2012)
Advances in the assessment and control of the effector functions of therapeutic antibodies
Xu-Rong Jiang et al.
NATURE REVIEWS DRUG DISCOVERY (2011)
Alterations in the antigen processing-presenting machinery of transformed plasma cells are associated with reduced recognition by CD8+ T cells and characterize the progression of MGUS to multiple myeloma
Vito Racanelli et al.
BLOOD (2010)
Share Paper
